ReviewInfection ecology & epidemiology2014
Overview of ESBL-producing Enterobacteriaceae from a Nordic perspective.
Review in Infection ecology & epidemiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it, 104 citations in OpenAlex.
- Extended-spectrum β-lactamase production and antimicrobial resistance among Enterobacteriaceae causing clinical infections in Africa: a systematic review and meta-analysis (2012-2020).European journal of medical research · 2025Pooled it
- Insights into antimicrobial resistance: dissemination and molecular epidemiology of carbapenemase and AmpC genes in uropathogenic Escherichia coli.BMC microbiology · 2026Article
- Article
- Isolation of ESBL-ProducingMicroorganisms · 2025Article
- The effect of the administration form of antibiotic therapy on the gut microbiome in patients with infected diabetic foot ulcers - DFIATIM trial.BMC microbiology · 2025Article
- Cockroaches as Reservoirs, Vectors, and Potential Sentinels of Multidrug-Resistant Bacteria in Ugandan Communities: A Retrospective Analysis.Global health, epidemiology and genomics · 2025Article
- Whole genome-based characterization of extended-spectrumNew microbes and new infections · 2024Article
- Resolved genomes of wastewater ESBL-producingMicrobiology spectrum · 2024Article
- Edible river fish-derived extended-spectrum β-lactamase (ESBL)-producing Enterobacterales harboring transferable plasmids encodingOne health (Amsterdam, Netherlands) · 2024Article
- Review
- High Prevalence of Plasmid-Mediated Quinolone Resistance among ESBL/AmpC-Producing Enterobacterales from Free-Living Birds in Poland.International journal of molecular sciences · 2023Article
- Antimicrobial Resistance Patterns and Risk Factors Associated with ESBL-Producing and MDRMicroorganisms · 2023Article
- Building an International One Health Strain Level Database to Characterise the Epidemiology of AMR Threats: ESBL-AmpC ProducingAntibiotics (Basel, Switzerland) · 2023Article
- Bacterial Co-Infections and Antimicrobial Resistance in Patients Hospitalized with Suspected or Confirmed COVID-19 Pneumonia in Kazakhstan.Pathogens (Basel, Switzerland) · 2023Article
- A spectrum of non-spore-forming fermentative and non-fermentative Gram-negative bacteria: multi-drug resistance, extended-spectrum beta-lactamase, and carbapenemase production.Frontiers in antibiotics · 2023Article
- Systematic Review and Meta-analysis on Extended-Spectrum β-lactamases ProducingMicrobiology insights · 2023Review
- Panorama of Bacterial Infections Caused by Epidemic Resistant Strains.Current microbiology · 2022Review
- Whole genome sequencing of the multidrug-resistantFrontiers in medicine · 2022Article
- Catheter-associated urinary tract infections in adult intensive care units at a selected tertiary hospital, Addis Ababa, Ethiopia.PloS one · 2022Article
- Antimicrobial resistance in patients with suspected urinary tract infections in primary care in Assam, India.JAC-antimicrobial resistance · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extended spectrum β-lactamases (ESBL) are increasing rapidly worldwide. E. coli producing CTX-M type ESBLs are the most common clinically encountered. The majority of E. coli ESBL infections are represented by urinary tract infections, but they can also cause severe infections, for example, in the blood stream and central nervous system. Since E. coli is a common colonizer of the normal gut microbiota, increasing prevalence of ESBL-producing strains is particularly worrisome. Once disseminated in the community, containment of this resistance type will be challenging. The driver of ESBL-producing Enterobacteriaceae (EPE) is debated. Some suggest that the ESBL genes were introduced to particularly successful bacterial clones. Others imply that very successful plasmids drive the rapid dissemination. More research and epidemiological studies of strain types, plasmids and mobile genetic elements are needed for these questions to be answered. In order to combat, or at least slow down, the worrisome trend of increasing numbers of EPE more knowledge is also needed on persistence of EPE in carriers as well as better understanding of how antibiotic treatment and other risk factors affect persistence and further dissemination. This review aims at giving an overview of this global problem from a Nordic perspective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.